Harpreet Singh, Chief Medical Officer at Precision For Medicine, shared a post on LinkedIn:
“Exciting news in colorectal cancer treatment! The FDA has granted accelerated approval for adagrasib + cetuximab, targeting KRAS G12C mutations.
Key takeaways from my latest video:
- First KRAS G12C targeting drug approved for colorectal cancer
- 34% overall response rate in the KRYSTAL-1 trial
- Addresses ~4% of colorectal cancer patients with this specific mutation
- KRAS was previously considered ‘undruggable’ in this cancer type
- This approval marks a significant step forward in precision medicine for colorectal cancer.
The KRYSTAL-10 confirmatory trial is now fully enrolled, and its results could potentially convert this to a full FDA approval.
What are your thoughts on targeting previously ‘undruggable’ mutations? What impact do you see long-term?
Follow for more.”
Proceed to the video attached to the post.
Source: Harpreet Singh/LinkedIn
More posts by Harpreet Singh in OncoDaily.